MedPath

A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference

Not Applicable
Completed
Conditions
Body Sculpting
Interventions
Device: Non Invasive Ultrasound
Registration Number
NCT01462201
Lead Sponsor
UltraShape
Brief Summary

The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment.

The secondary objective of this study is to assess subject satisfaction measured with a self-assessment questionnaire

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
156
Inclusion Criteria
  1. Female or male subjects, 18 and 65 years of age at the time of enrollment

  2. Abdominal fat thickness of at least 1.5 cm (measurement by caliper)

  3. For women of child-bearing potential:

    1. negative urine pregnancy test.
    2. Women of child bearing age are required to be using an acceptable form of birth control for the duration of the study.
  4. General good health confirmed by medical history and skin examination of the treated area

  5. Written informed consent to participate in the study

  6. Ability to comply with the requirements of the study

  7. BMI ≤ 30

    Intra-procedural Inclusion criteria (prior to starting the treatment phase):

    subjects are eligible to continue the study and participate in the treatment phase if she meets all of the following intra-procedural inclusion criteria:

  8. For women of child-bearing potential: negative pregnancy test

  9. Abdominal fat thickness of at least 1.5 cm prior to initial treatment (measurement by caliper)

Exclusion Criteria
  1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurysm
  2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease or malignancy.
  3. Previous liposuction in the treatment area
  4. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
  5. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
  6. Poor skin quality (i.e., laxity)
  7. Abdominal wall diastasis or hernia on physical examination
  8. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
  9. Obesity (BMI > 30)
  10. Childbirth within the last 12 months or breastfeeding women.
  11. Any acute or chronic condition which, in the opinion of the Investigator, could interfere with the conduct of the study
  12. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
  13. Inability to comply with circumference measurement procedure (e.g., inability to held breath for the required duration)
  14. Participation in another clinical study within the last six months.
  15. Previous body contouring treatments in the areas of the abdomen and flanks.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1 - Non Invasive UltrasoundNon Invasive UltrasoundGroup 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
Group 2 - Non Invasive UltrasoundNon Invasive UltrasoundGroup 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
Primary Outcome Measures
NameTimeMethod
The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment5-6 months

Reduction in circumference measurement of the abdomen from baseline

Secondary Outcome Measures
NameTimeMethod
Assess subject satisfaction measured with a self-assessment questionnaire5-6 months

Trial Locations

Locations (5)

MD Laser Skin & Vein Institute

🇺🇸

Hunt Valley, Maryland, United States

Dr. William Patrick Coleman, III

🇺🇸

Metairie, Louisiana, United States

New-Jersey Plastic Surgery

🇺🇸

Montclair, New Jersey, United States

Dr. Jeffrey Kenkel

🇺🇸

Dallas, Texas, United States

Department of Plastic Surgery and Burns Rabin Medical Center - Beilinson Hospital

🇮🇱

Petah Tikva, Israel

© Copyright 2025. All Rights Reserved by MedPath